Cemiplimab
Brand: Libtayo (global)
Anticancer
PD-1 monoclonal antibody
Pharmacokinetics
| Half-life | 19 days |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | IV infusion schedule based dosing. Half-life ~19 days. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Immune mediated pneumonitis, colitis, hepatitis, endocrinopathies
Contraindications:
Severe autoimmune disease
Precautions:
Monitor thyroid, liver, stool frequency. Treat immune toxicity with steroids.